Skip to main content
Top
Published in: Endocrine Pathology 2/2020

01-06-2020 | Neuroendocrine Tumor

Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors

Authors: Müjdat Kara, Fatma Tokat, M. Necmettin Pamir, Ayça Ersen Danyeli

Published in: Endocrine Pathology | Issue 2/2020

Login to get access

Abstract

The underlying mechanisms of aggressive pituitary neuroendocrine tumors (pitNETs) are still unclear. The p16 protein, encoded by the CDKN2A tumor suppressor gene on chromosome 9p21, is commonly reported to be lost in numerous types of cancer. For this reason, this study examined to examine the status of homozygous deletion of CDKN2A in high-risk pitNETs. Thirty-eight high-risk pitNETs (30 male, 8 female) were analyzed for CDKN2A deletion by fluorescent in situ hybridization (FISH). Demographic characteristics such as sex, patient age at operation, and sellar magnetic resonance imaging findings including tumor size and invasion status were recorded. The frequency of CDKN2A homozygous deletion by FISH was 3/38 (7.89%) in the high-risk pitNET group. All of these three cases with CDKN2A homozygous deletion were invasive densely granulated lactotroph tumors (p = 0.000). CDKN2A deletion was not correlated with patient age, sex, cavernous sinus invasion (CSI), and tumor size (p > 0.05). The Ki-67 proliferation index was significantly correlated with CDKN2A homozygous deletion (p = 0.003). The mean Ki-67 proliferation index was 10.7% in pitNETs with CDKN2A homozygous deletion and the Ki-67 proliferation index in the whole study group was 4.1%. CSI was significantly correlated with the morphofunctional tumor types including lactotroph tumor, invasive null cell tumor, and invasive gonadotroph tumor (p = 0.021). These findings suggest a close correlation between inactivation of p16 gene and invasive lactotroph tumors. Further investigations are needed to expand on the mechanism of p16 (CDKN2A) gene deletion in high-risk pitNETs.
Literature
1.
go back to reference Colao A, Grasso LF, Pivonello R, Lombardi G.: Therapy of aggressive pituitary tumors. Expert Opin Pharmaco. 12:1561–1570 (2011)CrossRef Colao A, Grasso LF, Pivonello R, Lombardi G.: Therapy of aggressive pituitary tumors. Expert Opin Pharmaco. 12:1561–1570 (2011)CrossRef
2.
go back to reference Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, de Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wémeau JL, de Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91: 3316–3323 (2006)CrossRef Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, de Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wémeau JL, de Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91: 3316–3323 (2006)CrossRef
3.
go back to reference Theodros D, Patel M, Ruzevick J, Lim M, Bettegowda C.: Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol. 4(6):411–429 (2015)CrossRef Theodros D, Patel M, Ruzevick J, Lim M, Bettegowda C.: Pituitary adenomas: historical perspective, surgical management and future directions. CNS Oncol. 4(6):411–429 (2015)CrossRef
4.
go back to reference Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol Sep;28(3):228–243 (2017)CrossRef Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol Sep;28(3):228–243 (2017)CrossRef
5.
go back to reference Inoshita N, Nishioka H.: The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol. Apr;35(2):51–56 (2018)CrossRef Inoshita N, Nishioka H.: The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol. Apr;35(2):51–56 (2018)CrossRef
7.
go back to reference Shapiro GI.: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770–1783 (2006)CrossRef Shapiro GI.: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770–1783 (2006)CrossRef
8.
go back to reference Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T, Fukushima T: The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398–403 (2005)CrossRef Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T, Fukushima T: The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398–403 (2005)CrossRef
9.
go back to reference Roussel MF.: The INK4 family of cell cycle inhibitors in cancer. Oncogene. 18: 5311–5317 (1999)CrossRef Roussel MF.: The INK4 family of cell cycle inhibitors in cancer. Oncogene. 18: 5311–5317 (1999)CrossRef
10.
go back to reference Woloschak M, Yu A, Post KD.: Frequent inactivation of the p16 gene in human pituitary tumours by gene methylation. Mol Carcinogen 19: 221–224 (1997)CrossRef Woloschak M, Yu A, Post KD.: Frequent inactivation of the p16 gene in human pituitary tumours by gene methylation. Mol Carcinogen 19: 221–224 (1997)CrossRef
11.
go back to reference Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R, Paulus W: CDKN2A /p16 inactivation is related to pituitary adenoma type and size. J Pathol 193: 491–497 (2001)CrossRef Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R, Paulus W: CDKN2A /p16 inactivation is related to pituitary adenoma type and size. J Pathol 193: 491–497 (2001)CrossRef
13.
go back to reference Lloyd RV, Osamura RY, Kloppel G, Rosai J.: WHO classification of tumours of endocirne organs, 4th edn. International Agency for Research on Cancer, Lyon 3. (2017) Lloyd RV, Osamura RY, Kloppel G, Rosai J.: WHO classification of tumours of endocirne organs, 4th edn. International Agency for Research on Cancer, Lyon 3. (2017)
15.
go back to reference Mastronardi L, Guiducci A, Puzzilli F.: Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12 (2001)CrossRef Mastronardi L, Guiducci A, Puzzilli F.: Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12 (2001)CrossRef
16.
go back to reference Peker S, Kurtkaya-Yapıcıer O, Kılıc T, Pamir MN.: Microsurgical anatomy of the lateral walls of the pituitary fossa. Acta Neurochir (Wien). 147(6):641–648; discussion 649. Epub 2005 Apr 4. (2005).CrossRef Peker S, Kurtkaya-Yapıcıer O, Kılıc T, Pamir MN.: Microsurgical anatomy of the lateral walls of the pituitary fossa. Acta Neurochir (Wien). 147(6):641–648; discussion 649. Epub 2005 Apr 4. (2005).CrossRef
17.
go back to reference Sclon MF, Peters JR, Thomas JP, Richards SH, Morton WH, et al.: Management of selected patients with hyperprolactinaemia by partial hypophysectomy. Br Med J (Clin Res Ed) 291:1547–1550 (1985)CrossRef Sclon MF, Peters JR, Thomas JP, Richards SH, Morton WH, et al.: Management of selected patients with hyperprolactinaemia by partial hypophysectomy. Br Med J (Clin Res Ed) 291:1547–1550 (1985)CrossRef
18.
go back to reference Serri O, Rasio E, Beauregard H, Hardy J, Somma M.: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J. Med 309:280–283 (1983)CrossRef Serri O, Rasio E, Beauregard H, Hardy J, Somma M.: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J. Med 309:280–283 (1983)CrossRef
19.
go back to reference Congxin Dai, Ming Feng, Xiaohai Liu, Sihai Ma, Bowen Sun, et al.: Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget. Dec 13; 7(50): 83657–83668 (2016)CrossRef Congxin Dai, Ming Feng, Xiaohai Liu, Sihai Ma, Bowen Sun, et al.: Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget. Dec 13; 7(50): 83657–83668 (2016)CrossRef
20.
go back to reference Lu JG, Huang ZQ, Wu JS, Wang Q, Ma QJ, et al.: Significance of tumor suppressor gene p16 expression in primary biliary cancer. Shijie Huaren Xiaohua Zazhi. 8: 638–640 (2000) Lu JG, Huang ZQ, Wu JS, Wang Q, Ma QJ, et al.: Significance of tumor suppressor gene p16 expression in primary biliary cancer. Shijie Huaren Xiaohua Zazhi. 8: 638–640 (2000)
21.
go back to reference Serrano M, Hannon GJ, Beach D.: A new regulatorymotif in cellcycle control causing specific ihhibition of cyclin D/CDK4. Nature. 366: 704–707 (1993)CrossRef Serrano M, Hannon GJ, Beach D.: A new regulatorymotif in cellcycle control causing specific ihhibition of cyclin D/CDK4. Nature. 366: 704–707 (1993)CrossRef
22.
go back to reference Tam KW, Zhang W, Soh J, Stastny V, Chen M, Marconett CN, et al: CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol 8: 1378–1388 (2013)CrossRef Tam KW, Zhang W, Soh J, Stastny V, Chen M, Marconett CN, et al: CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol 8: 1378–1388 (2013)CrossRef
23.
go back to reference Riehmer V, Gietzelt J, Beyer U, Hentschel B,: Westphal M, Schackert G, Sabel MC, Radlwimmer B, Pietsch T, Reifenberger G, et al: Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes Chromosomes Cancer 53: 589–605 (2014)CrossRef Riehmer V, Gietzelt J, Beyer U, Hentschel B,: Westphal M, Schackert G, Sabel MC, Radlwimmer B, Pietsch T, Reifenberger G, et al: Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes Chromosomes Cancer 53: 589–605 (2014)CrossRef
24.
go back to reference Shi ZZ, Shang L, Jiang YY, Hao JJ, Zhang Y, Zhang TT, Lin DC, Liu SG, Wang BS, Gong T, Zhan QM, Wang MR: Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization. Clin Cancer Res 19: 5867–5878 (2013)CrossRef Shi ZZ, Shang L, Jiang YY, Hao JJ, Zhang Y, Zhang TT, Lin DC, Liu SG, Wang BS, Gong T, Zhan QM, Wang MR: Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization. Clin Cancer Res 19: 5867–5878 (2013)CrossRef
25.
go back to reference Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220–228 (2010)CrossRef Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220–228 (2010)CrossRef
26.
go back to reference Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 60:314–322 (1994)CrossRef Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 60:314–322 (1994)CrossRef
27.
go back to reference Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, et al.: Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. Oct; 21(5):454–462 (2018)CrossRef Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, et al.: Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. Oct; 21(5):454–462 (2018)CrossRef
Metadata
Title
Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors
Authors
Müjdat Kara
Fatma Tokat
M. Necmettin Pamir
Ayça Ersen Danyeli
Publication date
01-06-2020
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2020
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-020-09609-2

Other articles of this Issue 2/2020

Endocrine Pathology 2/2020 Go to the issue